The European Medicines Agency has approved a new label claim forProMeris Duo for dogs, which extends protection offered by the product to include “treatment of demodicosis (caused by Demodexspp.) and lice (Trichodectes canis) in dogs”.
Rami Cobb, senior vice-president of pharmaceutical research and development at Fort Dodge Animal Health, said: “With the addition of the demodectic mange claim to the ProMeris Duo label, veterinarians have the option of using the recognized efficacy of amitraz in a convenient spot-on formulation to treat and control this condition.
“When we conducted field studies for the label claim, the before and after pictures of the dogs treated with ProMeris Duo were remarkable. Visible improvements in the dog’s condition were seen following the first treatment and in most cases, demodex mites could not be found after just a few months.”
According to Fort Dodge, ProMeris Duo was evaluated for efficacy against demodectic mange mites in naturally infected dogs. Study results indicated dogs treated monthly with ProMeris Duo showed significant reduction in mite numbers and improvement in clinical signs after three months.
ProMeris Duo is now licensed for the following indications: For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), as well as ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).